EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study

Hira Tanvir iD, Rebecca A Clark iD, Tom Sumner iD, Katherine C Horton iD, Tomos O Prŷs-Jones iD, Roel Bakker iD, Kirankumar Rade iD, Vidya Mave iD, Mark Hatherill iD, Gavin J Churchyard iD, Rein M G J Houben iD, Richard G White iD

PLOS Medicine · 12.02.2026 · 23 (2) · e1004595

DOI: 10.1371/journal.pmed.1004595 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Medicine, online erschienen am 12.02.2026. Verfasst von Hira Tanvir und 11 weiteren Autor:innen. Beteiligte Einrichtung: TB Modelling Group, TB Centre, and Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London Sc…. Hauptthemen laut MEDLINE: Tuberculosis Vaccines, Tuberculosis, Vaccine Efficacy, Asymptomatic Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tuberculosis (TB) remains a leading cause of infectious disease death. New TB vaccines are currently in late-stage trials and may be available before the end of the decade. Modelling predicts new TB vaccines may reduce global burden but rely on assumptions about vaccine efficacy by TB disease stage and TB natural history, which may be incorrect. We explored the sensitivity of estimates of the impact of new TB vaccines to uncertainties in efficacy by disease stage and natural history. Methods and findings We developed a dynamic compartmental TB model for India, including early TB disease stages (non-infectious disease, infectious asymptomatic disease, and infectious symptomatic disease). Scenarios assumed 50% vaccine efficacy for 10 years and prevented progression to (a) only infectious symptomatic disease, or (b) any infectious disease (infectious asymptomatic disease and infectious symptomatic disease), or (c) any disease (non-infectious disease, infectious asymptomatic disease, and infectious symptomatic disease). We estimated impact on averting disease episodes over 2030–2050, compared to no-new-vaccine introduction. Results suggest, over 3 years, there was little difference in the proportion of cumulative symptomatic disease episodes averted by vaccines preventing only infectious symptomatic disease, any infectious disease, or any disease (1.6%, 2.3%, and 2.3%, respectively). However, over 20 years, compared to vaccines preventing only infectious symptomatic disease, vaccines preventing any infectious disease, or any disease, averted a markedly higher proportion of symptomatic disease episodes (7.3%, 19.4%, and 23.3%, respectively), due to preventing continued transmission from infectious asymptomatic disease. A key limitation with any mathematical modelling study is the uncertainty associated with the inputs, and further data collection is required to better understand the transmissibility, morbidity, and dynamics of asymptomatic disease, to improve modelling estimates and inform wider policy.

Conclusions

Our modelling estimates that the population impact of new TB vaccines may depend on efficacy against infectious asymptomatic disease. TB vaccine trials should include analyses of participant sputum samples (collected during or at the end of trials and analysed at the end of trials) to enable better estimates of the potential value of new TB vaccines against infectious asymptomatic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis VaccinesTuberculosisVaccine EfficacyAsymptomatic InfectionsHumansIndia

Substanzen

Tuberculosis Vaccines

Autor:innen und Institutionen

  • TB Modelling Group, TB Centre, and Centre for Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • Vaccine Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom.
  • KNCV Tuberculosis Foundation, The Hague, Netherlands.
  • Independent Consultant, New Delhi, India.
  • Byramjee-Jeejeebhoy Government Medical College, Johns Hopkins University Clinical Research Site, Pune, India.
  • South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Hira Tanvir, Rebecca A Clark, Tom Sumner, Katherine C Horton, Tomos O Prŷs-Jones, Roel Bakker, Kirankumar Rade, Vidya Mave, Mark Hatherill, Gavin J Churchyard, Rein M G J Houben, Richard G White

Förderung

  • NIAID NIH HHS
  • Bill and Melinda Gates Foundation

Zitieren

APA

Tanvir, H., Clark, R. A., Sumner, T., Horton, K. C., Prŷs-Jones, T. O., Bakker, R., Rade, K., Mave, V., Hatherill, M., Churchyard, G. J., Houben, R. M. G. J., & White, R. G. (2026). Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study. PLOS Medicine, 23(2), e1004595. https://doi.org/10.1371/journal.pmed.1004595

Vancouver

Tanvir H, Clark RA, Sumner T, Horton KC, Prŷs-Jones TO, Bakker R, et al. Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study. PLOS Medicine. 2026;23(2):e1004595. doi:10.1371/journal.pmed.1004595

BibTeX
@article{Tanvir2026,
  author = {Tanvir, Hira and Clark, Rebecca A and Sumner, Tom and Horton, Katherine C and Prŷs-Jones, Tomos O and Bakker, Roel and Rade, Kirankumar and Mave, Vidya and Hatherill, Mark and Churchyard, Gavin J and Houben, Rein M G J and White, Richard G},
  title = {Estimating the population impact of new tuberculosis vaccines depending on efficacy against infectious asymptomatic tuberculosis: A modelling study},
  journal = {PLOS Medicine},
  year = {2026},
  volume = {23},
  number = {2},
  pages = {e1004595},
  doi = {10.1371/journal.pmed.1004595}
}
Kostenlos starten →